Compass Pathways/$CMPS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Compass Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Ticker
$CMPS
Sector
Primary listing
Employees
166
Headquarters
Website
Compass Pathways Metrics
BasicAdvanced
$604M
-
-$2.74
1.94
-
Price and volume
Market cap
$604M
Beta
1.94
52-week high
$8.20
52-week low
$2.25
Average daily volume
1.4M
Financial strength
Current ratio
1.228
Quick ratio
1.146
Long term debt to equity
54.71
Total debt to equity
93.597
Interest coverage (TTM)
-34.27%
Profitability
EBITDA (TTM)
-154.377
Effective tax rate (TTM)
-0.54%
Management effectiveness
Return on assets (TTM)
-38.43%
Return on equity (TTM)
-205.81%
Valuation
Price to book
16.06
Price to tangible book (TTM)
16.06
Price to free cash flow (TTM)
-3.383
Free cash flow yield (TTM)
-29.56%
Free cash flow per share (TTM)
-1.859
Growth
Earnings per share change (TTM)
24.70%
3-year earnings per share growth (CAGR)
10.27%
What the Analysts think about Compass Pathways
Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.
Compass Pathways Financial Performance
Revenues and expenses
Compass Pathways Earnings Performance
Company profitability
Compass Pathways News
AllArticlesVideos
COMPASS Pathways Plc ADR (CMPS) Price Forecast: Bullish Reversal Gains Structure
FXEmpire·2 days ago
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD
Business Wire·1 month ago
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Compass Pathways stock?
Compass Pathways (CMPS) has a market cap of $604M as of February 12, 2026.
What is the P/E ratio for Compass Pathways stock?
The price to earnings (P/E) ratio for Compass Pathways (CMPS) stock is 0 as of February 12, 2026.
Does Compass Pathways stock pay dividends?
No, Compass Pathways (CMPS) stock does not pay dividends to its shareholders as of February 12, 2026.
When is the next Compass Pathways dividend payment date?
Compass Pathways (CMPS) stock does not pay dividends to its shareholders.
What is the beta indicator for Compass Pathways?
Compass Pathways (CMPS) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.